Header Logo

Connection

CARLOS RAMOS to Humans

Back to Details
This is a "connection" page, showing publications CARLOS RAMOS has written about Humans.
CARLOS RAMOS
Connection Strength
0.346
Humans
  1. Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematol Oncol Clin North Am. 2023 12; 37(6):1107-1124.
    View in: PubMed
    Score: 0.017
  2. Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell Transplant? Transplant Cell Ther. 2022 01; 28(1):1-2.
    View in: PubMed
    Score: 0.016
  3. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
    View in: PubMed
    Score: 0.015
  4. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
    View in: PubMed
    Score: 0.014
  5. Cellular Immunotherapy in Lymphoma: Beyond CART Cells. Curr Treat Options Oncol. 2020 02 11; 21(3):21.
    View in: PubMed
    Score: 0.014
  6. The CNS can be a safe space for CARs. Blood. 2019 09 12; 134(11):845-846.
    View in: PubMed
    Score: 0.013
  7. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.012
  8. Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J. 2018 Feb; 13(2).
    View in: PubMed
    Score: 0.012
  9. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
    View in: PubMed
    Score: 0.011
  10. Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. Mol Ther. 2017 01 04; 25(1):8-9.
    View in: PubMed
    Score: 0.011
  11. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.011
  12. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
    View in: PubMed
    Score: 0.010
  13. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
    View in: PubMed
    Score: 0.010
  14. CD19-CAR trials. Cancer J. 2014 Mar-Apr; 20(2):112-8.
    View in: PubMed
    Score: 0.009
  15. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76.
    View in: PubMed
    Score: 0.008
  16. Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia. Biol Blood Marrow Transplant. 2012 Jul; 18(7):975-6.
    View in: PubMed
    Score: 0.008
  17. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011 Jul; 11(7):855-73.
    View in: PubMed
    Score: 0.007
  18. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
    View in: PubMed
    Score: 0.007
  19. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):686-94.
    View in: PubMed
    Score: 0.007
  20. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009 Feb; 94(2):249-57.
    View in: PubMed
    Score: 0.006
  21. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 Dec; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.005
  22. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.005
  23. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.005
  24. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy. Cytotherapy. 2024 03; 26(3):261-265.
    View in: PubMed
    Score: 0.004
  25. Free human mitochondrial GrpE is a symmetric dimer in solution. J Biol Chem. 2003 Sep 12; 278(37):35337-44.
    View in: PubMed
    Score: 0.004
  26. T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy. Br J Haematol. 2023 08; 202(4):874-878.
    View in: PubMed
    Score: 0.004
  27. Techniques for the study of adult stem cells: be fruitful and multiply. Biotechniques. 2003 Mar; 34(3):572-8, 580-4, 586-91.
    View in: PubMed
    Score: 0.004
  28. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
    View in: PubMed
    Score: 0.004
  29. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
    View in: PubMed
    Score: 0.004
  30. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.004
  31. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022 05; 19(5):342-355.
    View in: PubMed
    Score: 0.004
  32. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. PLoS Comput Biol. 2022 03; 18(3):e1009883.
    View in: PubMed
    Score: 0.004
  33. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
    View in: PubMed
    Score: 0.004
  34. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
    View in: PubMed
    Score: 0.004
  35. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6.
    View in: PubMed
    Score: 0.004
  36. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.004
  37. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.004
  38. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020 09 23; 11(1):4810.
    View in: PubMed
    Score: 0.004
  39. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
    View in: PubMed
    Score: 0.004
  40. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
    View in: PubMed
    Score: 0.003
  41. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.003
  42. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020 01; 105(1):235-243.
    View in: PubMed
    Score: 0.003
  43. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
    View in: PubMed
    Score: 0.003
  44. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386.
    View in: PubMed
    Score: 0.003
  45. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.003
  46. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.003
  47. Risk factors for glenoid erosion in patients with shoulder hemiarthroplasty: an analysis of 118 cases. J Shoulder Elbow Surg. 2017 Feb; 26(2):246-252.
    View in: PubMed
    Score: 0.003
  48. Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
    View in: PubMed
    Score: 0.002
  49. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.002
  50. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
    View in: PubMed
    Score: 0.002
  51. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.002
  52. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.002
  53. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.002
  54. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
    View in: PubMed
    Score: 0.002
  55. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol. 2011 Nov; 86(11):961-2.
    View in: PubMed
    Score: 0.002
  56. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
    View in: PubMed
    Score: 0.002
  57. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
    View in: PubMed
    Score: 0.002
  58. [Association between meningeal Burkitt lymphoma and Epstein-Barr virus in an HIV-infected patient]. Enferm Infecc Microbiol Clin. 2007 Dec; 25(10):658.
    View in: PubMed
    Score: 0.001
  59. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol. 2006 May; 13(3):175-81.
    View in: PubMed
    Score: 0.001
  60. Heparin-binding sites in granulocyte-macrophage colony-stimulating factor. Localization and regulation by histidine ionization. J Biol Chem. 2005 Sep 09; 280(36):31949-56.
    View in: PubMed
    Score: 0.001
  61. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2004 Oct; 2(10):e301.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.